Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2013-03-14

Clinical Trial Update: Exenatide Versus Glimepiride in Patients With Type 2 Diabetes [Phase 3]

View source ↗

Summary

A Phase 3 head-to-head trial comparing exenatide with glimepiride in adults with type 2 diabetes has completed, with results posted in March 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Amaryl (glimepiride)
  • BYETTA (Exenatide)

Snippet

Sponsor: AstraZeneca | Conditions: Type 2 Diabetes Mellitus | Phase 3 | Status: COMPLETED | Results posted: 2013-03-14